CG200745 | 936221-33-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: CG200745
• 英文别名: Ivaltinostat；(E)-N-[3-(dimethylamino)propyl]-N'-hydroxy-2-(naphthalen-1-yloxymethyl)oct-2-enediamide
• CAS: 936221-33-9
• 化学式: C₂₄H₃₃N₃O₄
• 分子量: 427.544
• InChiKey: AUGCSOFQTDKPSO-RGVLZGJSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  31
• 可旋转键数：
  13
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  90.9
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  (E)-N1-(3-(dimethylamino)propyl)-2-((naphthalen-1-yloxy)methyl)-N8-(tetrahydro-2H-pyran-2-yloxy)octenediamide 以92的产率得到CG200745
  参考文献：
  名称：

  WO2007052938A1

  摘要：

  公开号：

文献信息

• METHOD OF TREATING VIRAL INFECTIONS
  申请人：EPIPHANY BIOSCIENCES

  公开号：US20150050241A1

  公开（公告）日：2015-02-19

  The present invention is directed to methods and compositions employing 9-(4-hydroxy-2-(hydroxymethyl)butyl)guanine (“H2G”) or derivatives or analogs thereof for the treatment of viral diseases, as well as for the treatment of other conditions, including, but not limited to, cancer, chronic fatigue syndrome, Alzheimer's disease, multiple sclerosis and Graves' disease. The H2G or derivative or analog thereof can be administered in a pharmaceutical composition and can be administered with an additional antiviral therapeutic agent or another agent for the treatment of other conditions.

  本发明涉及使用9-（4-羟基-2-（羟甲基）丁基）鸟嘌呤（“H2G”）或其衍生物或类似物的方法和组合物，用于治疗病毒性疾病，以及用于治疗其他疾病，包括但不限于癌症、慢性疲劳综合征、阿尔茨海默病、多发性硬化症和格雷夫斯病。 H2G或其衍生物或类似物可以在药物组合物中给予，并且可以与其他抗病毒治疗药物或其他治疗其他疾病的药物一起给予。
• PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF FIBROSIS
  申请人：Crystalgenomics, Inc.

  公开号：EP3777847A1

  公开（公告）日：2021-02-17

  The present invention relates to a pharmaceutical composition comprising alkylcarbamoyl naphthalenyloxy octenoyl hydroxyamide, a derivative thereof, or a pharmaceutically acceptable salt thereof as an effective ingredient for prevention or treatment of fibrosis. Effectively suppressing the proliferation of fibrous tissues, the composition can be used for preventing and/or treating fibrosis.

  本发明涉及一种药物组合物，该组合物包含烷基氨基甲酰基萘氧基辛烯酰羟酰胺、其衍生物或其药学上可接受的盐，作为预防或治疗纤维化的有效成分。该组合物能有效抑制纤维组织的增殖，可用于预防和/或治疗纤维化。
• PHARMACEUTICAL COMPOSITION CONTAINING ALKYL CARBAMOYL NAPHTHALENYLOXY OCTENOYL HYDROXYAMIDE PHOSPHATE, TARTRATE OR COMBINATION THEREOF, AND PREPARATION METHOD THEREFOR
  申请人：Crystalgenomics, Inc.

  公开号：EP3875081A1

  公开（公告）日：2021-09-08

  The present invention relates to a pharmaceutical composition containing an alkyl carbamoyl naphthalenyloxy octenoyl hydroxyamide phosphate compound (hereinafter referred to as CG200745PPA) or a derivative thereof, and can provide a pharmaceutical composition in a tablet, granule, powder, capsule, dry syrup or injection form. By providing the composition in various forms, a suitable form can be selected and easily applied when oral administration is difficult.

  本发明涉及一种含有烷基氨基甲酰萘氧基辛烯酰羟酰胺磷酸酯化合物（以下简称 CG200745PPA）或其衍生物的药物组合物，可提供片剂、颗粒剂、粉剂、胶囊剂、干糖浆剂或注射剂形式的药物组合物。通过提供各种形式的组合物，可以选择合适的形式，并在口服给药困难时方便应用。
• PHARMACEUTICAL COMPOSITION COMPRISING HDAC INHIBITOR AND ANTI-PD1 ANTIBODY OR ANTI PD-L1 ANTIBODY
  申请人：Crystalgenomics, Inc.

  公开号：EP4026544A1

  公开（公告）日：2022-07-13

  The present invention relates to a method for killing cancer cells by using a combination of an HDAC inhibitor and an anti-PD1 antibody or an anti PD-L1 antibody. The present invention can have an effective influence on: extending the survival of animals with cancer, tumors, tumor-related disorders and neoplastic diseases; inhibiting the growth of proliferative cells associated with neoplasms; or neoplastic degeneration.

  本发明涉及一种通过使用 HDAC 抑制剂和抗 PD1 抗体或抗 PD-L1 抗体的组合来杀死癌细胞的方法。本发明可对以下方面产生有效影响：延长癌症、肿瘤、肿瘤相关疾病和肿瘤性疾病动物的生存期；抑制与肿瘤相关的增殖细胞的生长；或肿瘤变性。
• Methods and compositions for the treatment of cancer cachexia
  申请人：Ohio State Innovation Foundation

  公开号：US11529323B2

  公开（公告）日：2022-12-20

  In one aspect, the disclosure relates to methods and compositions for treatment of cancer cachexia. In a further aspect, the composition is a pharmaceutical composition comprising a class I/IIB HDAC inhibitor and an androgen. In a still further aspect, the method of treatment comprises administering a class I/IIB HDAC inhibitor and an androgen to a subject or patient who has been diagnosed as having cancer cachexia. In some aspects, the class I/IIB HDAC inhibitor is a compound known as AR-42.

  在一个方面，本公开涉及治疗癌症恶病质的方法和组合物。在另一个方面，组合物是一种药物组合物，包含I/IIB类HDAC抑制剂和雄激素。在更进一步的方面，治疗方法包括向已被诊断为癌症恶病质的受试者或患者施用I/IIB类HDAC抑制剂和雄激素。在某些方面，I/IIB类HDAC抑制剂是一种称为AR-42的化合物。